TG Therapeutics Inc (NASDAQ:TGTX) Expected to Announce Earnings of -$0.43 Per Share

Equities research analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to report earnings per share of ($0.43) for the current quarter, Zacks reports. Two analysts have made estimates for TG Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.48). TG Therapeutics posted earnings of ($0.59) per share during the same quarter last year, which indicates a positive year over year growth rate of 27.1%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.30). For the next financial year, analysts forecast that the firm will report earnings of ($1.29) per share, with EPS estimates ranging from ($1.61) to ($0.87). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million.

TGTX has been the topic of several research analyst reports. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Cantor Fitzgerald initiated coverage on shares of TG Therapeutics in a research report on Friday, March 29th. They issued an “overweight” rating and a $17.00 target price on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of TG Therapeutics in a research report on Friday, April 12th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $14.07.

Shares of TGTX traded up $0.14 during mid-day trading on Friday, hitting $7.26. The company had a trading volume of 1,070,953 shares, compared to its average volume of 1,373,582. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.72 and a quick ratio of 1.72. TG Therapeutics has a 1-year low of $3.32 and a 1-year high of $14.65.

A number of hedge funds and other institutional investors have recently bought and sold shares of TGTX. LPL Financial LLC purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $49,000. NumerixS Investment Technologies Inc purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $50,000. Ladenburg Thalmann Financial Services Inc. raised its holdings in TG Therapeutics by 46.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 2,200 shares during the period. National Asset Management Inc. purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $58,000. Finally, Stifel Financial Corp purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 54.60% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Further Reading: What is a resistance level?

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.